Premium
Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma
Author(s) -
Lucas Kenneth G.,
Schwartz Cindy,
Kaplan Joel
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21503
Subject(s) - medicine , immunosuppression , sarcoma , blood cancer , stem cell , refractory (planetary science) , transplantation , human leukocyte antigen , graft versus host disease , cancer , antigen , oncology , surgery , pathology , immunology , physics , biology , astrobiology , genetics
Ewing sarcoma (ES) can express tumor antigens which can be recognized by T cells, making allogeneic stem cell transplant (SCT) a potential option for those patients with refractory disease. A 6‐year old with multifocal ES developed a recurrence of pulmonary metastases and underwent an allogeneic bone marrow transplant from her human leukocyte antigen (HLA) 10/10 matched mother. During a taper of her immunosuppression, she developed grade 1 skin and oral graft versus host disease (GVHD). CT scans performed 9 months post‐transplant revealed a marked decrease in the size of her pulmonary lesions compared to scans 2 months post‐transplant. This case highlights the possibility of treating patients with refractory metastatic ES with allogeneic SCT. Pediatr Blood Cancer 2008;51:142–144. © 2008 Wiley‐Liss, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom